Related Content
- New alliance will crack down on adulterated products touting dietary supplement claims
- FDA OKs Abilify as maintenance treatment for bipolar disorder
- K-V: FDA will approve Gestiva by PDUFA date
- FDA approves Novartis drug for high blood pressure treatment
- FDA approves Merck's Gardasil for prevention of anal cancer
TORONTO — Canadian drug maker Intellipharmaceutics International is seeking approval for a generic version of a treatment for mental disorders.
Intellipharmaceutics announced Monday that it had filed an application with the Food and Drug Administration for quetiapine fumarate extended-release tablets, a generic version of AstraZeneca’s Seroquel XR.
Seroquel XR is used to treat schizophrenia, bipolar disorder and major depressive disorder. It had sales of about $823 million in 2010, according to Intellipharmaceutics. The last of the patents covering Seroquel XR expire in 2017, according to FDA records.
